louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06908525: Norwegian Translation of the Things You Do Questionnaire 15-Item Version
Official title: A Translation Study of the Things You Do Questionnaire 15-Item Version
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: General Adult Population
Age 16 and Older
Keywords: Translation
TYDQ-15
Psychometric Evaluation
Lead sponsor: Haukeland University Hospital
Sponsor class: OTHER
First posted: 2025-04-03
Enrollment: 1000
Sex: ALL
Minimum age (years): 16
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: General population of Norway

Brief summary: Psychotherapy aims to modify dysfunctional patterns of thinking, feeling, and behaving to improve mental health. A five-factor model of adaptive behaviors, operationalized in the Things You Do Questionnaire (TYDQ), has been identified as a mediator of treatment response in depression and anxiety interventions. The short-form TYDQ-15 is a key component of a transdiagnostic treatment promoting adaptive behavior. To implement this intervention in Norway, the TYDQ-15 requires translation and cultural adaptation, following established guidelines for clinical assessment instruments. Currently unavailable in Norwegian, its translation and psychometric evaluation are necessary for clinical application. This study aims to (1) produce a culturally adapted Norwegian version of the TYDQ-15 and (2) assess its psychometric properties, including reliability, factor structure, and criterion validity, within a Norwegian population. The findings will facilitate the integration of the Things You Do Intervention into Norwegian mental health services.


Eligibility criteria: Inclusion Criteria:

* Age \> 16 years
* Native Norwegian speaker

Exclusion Criteria:

* Does not speak Norwegian fluently

Primary outcomes:
measure: Things You Do Questionnaire 15-Item Version (TYDQ-15)
timeFrame: Singe time point, at enrolment.
Secondary outcomes:
measure: The Patient Health Questionnaire (PHQ-9)
timeFrame: Single time point, at enrolment.
measure: The Generalized Anxiety Disorder Scale (GAD-7)
timeFrame: Single time point, at enrolment.
measure: The Satisfaction with Life Scale (SWLS)
timeFrame: Single time point, at enrolment.
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02874625: RCT to Evaluate Biocompatibility of Resin-based Dental Materials
Official title: Randomized Clinical Trial in Children to Evaluate the Biocompatibility of Resin-based Dental Materials
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Materials Testing
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
Collaborators: name: KU Leuven
First posted: 2016-08-22
Enrollment: 200
Sex: ALL
Minimum age (years): 4
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: In this randomized clinical trial, the bio-compatibility of 2 materials used for dental restorations will be compared: glass-ionomer vs resin-based composites.

Urine and saliva samples will be taken for determination of bisphenol A levels at several time points, and for analysis of the estrogenic activity using ERE-CALUX.

Also buccal cells will be taken. Next, DNA extraction will be done with a commercial kit. Global alterations in DNA methylation and DNA hydroxymethylation levels will be determined using UPLC-MS/MS.


Eligibility criteria: Inclusion Criteria:

* one or more carious lesions in primary molars that require treatment

Exclusion Criteria:

* carious lesions that already affected the dental pulp, large lesions requiring cusp replacement, presence of oral inflammatory conditions during the previous 2 weeks, carriage of a fixed or removable prosthesis/orthodontic appliance, chronic disease requiring intake of drugs, exposure to diagnostic X-rays in previous 2 months, previous dental restorations

Primary outcomes:
measure: Urinary bisphenol A levels
timeFrame: 1 year
measure: Salivary bisphenol A levels
timeFrame: 1 year
measure: %DNA methylation
timeFrame: 6 months
measure: %DNA hydroxymethylation
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: BIOMAT, Department of Oral Health Sciences
Study officials:
References:
Clinical trial NCT03622125: Decrease in Temperature as a Pagtonomic Sign by Scorpion Sting
Official title: Decrease in Temperature by Scorpion Sting: a Pagtonomic Sign
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Scorpion Stings
Lead sponsor: Mexican Red Cross
Sponsor class: OTHER
Collaborators: name: Instituto Bioclon S.A. de C.V.
First posted: 2018-08-09
Enrollment: 184
Sex: ALL
Minimum age (years): 3
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Person who has been scorpion sting and present signs and symptoms of poisoning to will applied a treatment in the city of León, Guanajuato

Brief summary: The scorpion sting is a medical disease, for the signs and symptoms presented; Sometimes patients do not know the animal that causes these symptoms; the bibliography marks the decrease in temperature as a sign to be presented.

Detailed description: The scorpion sting is a medical emergency where 184 patients from the state of Guanajuato were divided into 2 groups according to the type of antivenom administered, the dose of antivenom were at the discretion of the attending physician, Birmex (n = 117) and Alacramyn (n = 67) for the temperature record of the site of sting and other vital signs, this to compare it with the bibliography as a pathognomonic sign.

Eligibility criteria: Inclusion Criteria:

* Scorpion sting
* All sex
* 3 - 90 ages

Exclusion Criteria:

* Application of ice at the sting site

Primary outcomes:
measure: Temperature change
timeFrame: 0, 30 and 120 minutes
Secondary outcomes:
measure: Blood preasure
timeFrame: 0, 30 and 120 minutes
measure: Heart rate
timeFrame: 0, 30 and 120 minutes
measure: Respiratory rate
timeFrame: 0, 30 and 120 minutes
Other outcomes:
Locations:
city: León
country: Mexico
facility: Cruz Roja Mexicana, Delegación León
state: Guanajuato
Study officials:
References:
citation: Isbister GK, Bawaskar HS. Scorpion envenomation. N Engl J Med. 2014 Jul 31;371(5):457-63. doi: 10.1056/NEJMra1401108. No abstract available.
Clinical trial NCT06986525: Clinical Evaluation of Two Different Surgical Techniques With PRF in the Treatment of Multiple Gingival Recessions
Official title: A Prospective Split-Mouth Clinical Study Comparing Coronally Advanced Flap and Tunnel Techniques Combined With Platelet-Rich Fibrin in the Treatment of Multiple Gingival Recessions
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Gingival Recession
Keywords: gingival recessions
platelet rich fibrin
root coverage
Lead sponsor: Pamukkale University
Sponsor class: OTHER
First posted: 2025-05-23
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Split-mouth randomized design. Each participant receives both interventions, one per side of the mouth.
Primary purpose: TREATMENT

Brief summary: This prospective clinical study aims to evaluate and compare the effectiveness of coronally advanced flap (CAF) and tunnel techniques, both combined with platelet-rich fibrin (PRF), in the treatment of multiple Miller Class I-II gingival recessions. Eleven participants with bilateral defects will be treated using a split-mouth design. Periodontal parameters will be assessed at baseline, 3 months, and 6 months.

Detailed description: The objective of this prospective clinical trial is to compare two mucogingival surgical techniques-coronally advanced flap (CAF) and tunnel technique-used in combination with platelet-rich fibrin (PRF) for treating multiple Miller Class I-II gingival recessions. Eleven systemically healthy participants with bilateral gingival recessions will be enrolled. CAF+PRF will be applied on one side, and Tunnel+PRF on the contralateral side. Clinical parameters including plaque index, gingival index, bleeding on probing, probing depth, clinical attachment level, recession height and width, and keratinized tissue height will be recorded at baseline, 3 months, and 6 months. Root coverage outcomes and clinical attachment gain will be analyzed.

Eligibility criteria: Inclusion Criteria:

* Age 18 years or older
* Systemically healthy individuals
* Presence of bilateral Miller Class I-II multiple gingival recessions
* Good oral hygiene and willingness to follow instructions
* Signed informed consent

Exclusion Criteria:

* Use of tobacco or smoking
* Pregnancy or lactation
* Presence of systemic diseases affecting periodontal health
* Use of medications that may affect healing (e.g., corticosteroids)
* Periodontal surgery in the same area within the last 6 months

Primary outcomes:
measure: Change in Recession Height (RH)
timeFrame: Baseline and 6 Months
Secondary outcomes:
measure: Change in Clinical Attachment Level (CAL)
timeFrame: Baseline, 3 Months, and 6 Months
Other outcomes:
Locations:
city: Denizli
country: Turkey
facility: Pamukkale University, Faculty of Dentistry, Periodontology
Study officials:
affiliation: Pamukkale University Faculty of Dentistry, Department of Periodontology
name: Gizem TORUMTAY CİN, Assoc. Prof. Dr.
role: STUDY_DIRECTOR
References:
Clinical trial NCT01448525: Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypotrichosis
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2011-10-07
Enrollment: 88
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine patient satisfaction with LATISSE® treatment for increasing eyelash prominence.


Eligibility criteria: Inclusion Criteria:

* Have inadequate eyelashes
* Never used prescription eyelash growth products

Exclusion Criteria:

* No visible eyelashes
* Permanent eyeliner or eyelash implants
* Semi-permanent eyelash tint, dye, or extensions within 3 months
* Over-the-counter eyelash growth products within 6 months
* Any disease, infection or abnormality of the eye or area around the eye
* Eye surgery within 3 months, or the anticipated need for eye surgery during the study
* Unable or unwilling to keep contact lenses out during drug application and for 30 minutes after application

Primary outcomes:
measure: Percentage of Participants Who Are Satisfied or Very Satisfied With Their Eyelashes Overall
timeFrame: Week 16
Secondary outcomes:
measure: Percentage of Participants With at Least a 1-Grade Increase in the Global Eyelash Assessment (GEA) Score
timeFrame: Baseline, Week 16
Other outcomes:
Locations:
city: Coral Gables
country: United States
state: Florida
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT04500925: The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience
Official title: The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Well Differentiated Thyroid Carcinoma
Papillary Thyroid Cancer
Keywords: Low risk, Risk stratification, Partial thyroidectomy, Hemithyroidectomy, Completion Thyroidectomy
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2020-08-05
Enrollment: 301
Sex: ALL
Minimum age (years): 38
Maximum age (years): 61
Standard ages: ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The medical charts of all patients who underwent thyroid surgery between January 2006 and December 2018 in TASMC were retrieved. Most of them were females. The mean age of the entire cohort was 49.59 ± 15.17 years (median 50 years, interquartile range 38-61\].

Brief summary: Background After diagnosing well-differentiated thyroid cancer (WDTC), careful assessment of the risk for disease-specific recurrence is essential for deciding between partial (low risk) and completion (high risk) thyroidectomies. Patients' preoperatively determined risk levels are re-stratified according to surgical and final histopathological findings. The American Thyroid Association 2015 guidelines suggest that patients with WDTC between 1-4 cm in size and without suspicious features may be suitable candidates for partial thyroidectomy. The incidence and clinical implications of high-risk features discovered postoperatively in patients with preoperatively determined low-risk WDTC have not been previously reported.

Methods All thyroidectomies performed between 2006-2018 in the Tel Aviv Sourasky Medical Center were included. Pre- and postoperative risk stratifications were performed, and the rate of completion thyroidectomy was determined. Patients with 1-4 cm WDTC without evidence of positive cervical lymph nodes, invasion to adjacent structures, or high-risk cytology were considered at low risk for disease-specific recurrence and therefore suitable for lobectomy.


Eligibility criteria: Inclusion Criteria:

* All patients who underwent thyroid surgery (partial and total) between 2006-2018 at Tel Aviv Sourasky Medical Center (TASMC) were included

Exclusion Criteria:

* Patients with evidence of cervical lymph node metastasis, other malignancies, adverse imaging features (i.e., extracapsular spread of thyroid malignancy, vocal cord paralysis or immobility in physical examination) were excluded from the study.

Primary outcomes:
measure: disease-specific recurrence
timeFrame: 2006-2018
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05613725: OptiGon - Optimising Laboratory Assays for Immune Responses to Gonococcus
Official title: Optimising Laboratory Assays for Immune Responses to Gonococcus
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gonorrhea
Lead sponsor: University of Oxford
Sponsor class: OTHER
First posted: 2022-11-14
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults (18-50 years) attending Oxford University Hospitals NHS Foundation Trust with confirmed untreated N. gonorrhoea infection

Brief summary: This is an observational study. Blood from otherwise healthy patients presenting with confirmed N.gonorrhoea infection, prior to treatment, will be collected to (i) allow the optimisation of assays assessing the immune response to gonococcus and (ii) assess whether N. gonorrhea specific responses can be detected on ELIspot +/- flow cytometry.

The investigators plan to recruit up to 30 adults (men and women, aged 18-50 years) who have been diagnosed with confirmed N.gonorrhoea infection at the Sexual Health Clinic at the Oxford University Hospitals NHS Foundation Trust. The investigators will collect blood samples from consenting participants prior to them receiving curative antibiotic treatment.

Detailed description: On the day the patient attends the Sexual Health Clinic, they will be given the PIS to consider participation to the study following a confirmed positive result for N. gonorrhoea infection. Following written informed consent, a venous blood sample will be collected (up to 26 ml) on the same day. This will conclude that participant's involvement to the study.

The blood sample will be transported to the laboratory at the Jenner Institute, University of Oxford for further analysis.

Eligibility criteria: Inclusion Criteria:

* Adults (18-50 years) attending Oxford University Hospitals NHS Foundation Trust with untreated confirmed N. gonorrhoea infection confirmed by either:

  * Nucleic acid test
  * Microscopy of urethral discharge

Exclusion Criteria:

* Have already received antimicrobial therapy to treat the N. gonorrhoea infection
* Have not provided written, informed consent.
* Presence of any known medical condition which, in the opinion of the local investigator, makes the donation of 26 mls of blood unsafe.

Primary outcomes:
measure: Cellular immune response
timeFrame: Blood sampling at enrolment
Secondary outcomes:
Other outcomes:
Locations:
city: Oxford
country: United Kingdom
facility: Oxford University Hospitals NHS Foundation Trust
Study officials:
affiliation: University of Oxford
name: Calman MacLennan
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02541825: Using Covered Stent of Diameter of 7mm in TIPS
Official title: Using Covered Stent of Diameter of 7mm in a Prospective, Single Blind, Randomized, Controlled Study of TIPS(Transjugular Intrahepatic Portosystemic Stent Shunt )
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Liver Disease
Keywords: transjugular intrahepatic portosystemic shunt
Lead sponsor: Beijing Shijitan Hospital, Capital Medical University
Sponsor class: OTHER
First posted: 2015-09-04
Enrollment: 216
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates the incidence of hepatic encephalopathy between covered stent of diameter of 7mm and 8mm in TIPS(transjugular intrahepatic portosystemic stent shunt ).Half of the participants will receive stent of diameter of 7mm ,while the other half will receive stent of diameter of 8mm.

Detailed description: TIPS is effective in the treatment of hemorrhage of digestive tract and intractable ascites,which are the complications of cirrhosis. At present, the high incidence of hepatic encephalopathy has been a major problem after TIPS. The high incidence rate of hepatic encephalopathy was closly associated with the diameter of the stent. We often use the stent of diameter 8mm in TIPS.In this study, we try to use the stent of smaller diameter of 7mm in TIPS,and compare the incidence of hepatic encephalopathy between the stent of diameter of 7mm and 8mm .

Eligibility criteria: Inclusion Criteria:

1. there is a clear TIPS treatment indications of liver cirrhosis portal hypertension patients of gastrointestinal bleeding.
2. undergoing elective TIPS to treat patients.
3. aged 18-70 years old

Exclusion Criteria:

1. preoperative patients with hepatic encephalopathy.
2. with portal vein thrombosis patients.
3. combined liver malignant tumor or other parts of the patients with malignant tumor.
4. In combination of peptic ulcer bleeding.

Primary outcomes:
measure: The incidence of hepatic encephalopathy after TIPS
timeFrame: 1 year
Secondary outcomes:
measure: the incidence of shunt restenosis after TIPS
timeFrame: 1 year
measure: the recurrence rate of gastrointestinal bleeding after TIPS
timeFrame: 1 year
measure: Portal venous pressure before and afterTIPS
timeFrame: 1 year
measure: liver function in different periods
timeFrame: 1 year
measure: blood ammonia in different periods
timeFrame: 1 year
measure: jaundice index in different periods
timeFrame: 1 year
measure: platelet count in different periods
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
affiliation: Beijing Shijitan Hospital, Capital Medical University
name: Jianli Xu, MD PhD
role: STUDY_CHAIR
References:
Clinical trial NCT01509222: Changing Dietary Patterns: an Individually Tailored Nutrition Intervention (OKE-study)
Official title: Changing Dietary Patterns: an Individually Tailored Nutrition Intervention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Keywords: Health promotion
Dietary Counseling
Lead sponsor: Wageningen University
Sponsor class: OTHER
First posted: 2012-01-12
Enrollment: 186
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The main objective of this study is to investigate the effect of a personalized nutrition intervention on the dietary pattern of apparently healthy adults with one or more children aged 4 to 12 years.

Detailed description: Giving personalized nutrition advice is perceived to be more effective in changing dietary patterns than giving general information about healthy eating.

Eligibility criteria: Inclusion Criteria:

* At least aged 18 years
* Having one child aged 4 to 12 years
* Written informed concent has been obtained

Exclusion Criteria:

* Not meeting the inclusion criteria
* Unable or unwilling to comply with the study procedures
* Enrolled in another study during the same study period
* Not being able to communicate (read, speak and write) in the Dutch language
* Having a partner who has been enrolled in the study
* Being pregnant or lactating during the study period or planning to become pregnant during the study period
* Having a BMI lower than 18.5 or higher that 35 kg/m2
* Using medication to lower cholesterol or being under control by a doctor for having too high cholesterol levels
* Using medication to lower blood pressure or being under control by a doctor for having a high blood pressure.
* Having diabetes type I or type II
* Following a diet (medical or self-initiated) or planning to follow a diet during the study period
* Undergoing a medical treatment that interferes with the intervention.
* Having gained or lost more than 5 kg of body weight during the last 6 months.

Primary outcomes:
measure: Changes in dietary pattern
timeFrame: baseline and 6 months
Secondary outcomes:
measure: Dietary behaviour
timeFrame: baseline and 6 months
measure: Health outcomes
timeFrame: baseline and 6 months
measure: Markers of intake
timeFrame: baseline and 6 months
Other outcomes:
Locations:
city: Wageningen
country: Netherlands
facility: Wageningen University
state: Gelderland
Study officials:
affiliation: Departement Human Nutrition, Wageningen University
name: Jeanne HM De Vries, Dr.
role: PRINCIPAL_INVESTIGATOR
References: